Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Szczegóły

Tytuł:: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Autorzy:: Evans, Abigail
Ball, Adrian
Johri, Akhil
Nejim, Ali
Jones, Alison
Corder, Allan
Thorne, Amanda
Anand, Ambika
Chakrabarti, Amitabha
Robinson, Anne
Skene, Anthony
Modi, Anupam
Patel, Ashraf
Kothari, Ashutosh
McFall, Brendan
Mortimer, Caroline
Lee, Caroline
Chan, Charlie
Abson, Charlotte
Holcombe, Christopher
Hinton, Christopher
Hollywood, Ciaran
Murphy, Claire
Crowley, Clare
Harding-Mackean, Claudia
Griffith, Clive
Lewanski, Conrad
Rea, Daniel
Hwang, David
Crawford, Derek
Thekkinkattil, Dinesh
Ferguson, Douglas
Adamson, Douglas
Wheatley, Duncan
Ravichandran, Duraisamy
Babu, Ed
Hyett, Elaine
Ashkanani, Fawzia
Hoar, Fiona
Kenny, Frances
Dyke, Gary
Sparrow, Geoffrey
Gilbert
Cunnick, Giles
Algurafi, Hafiz
Sweetland, Helen
Prof, Highes-Davies
Hamed, Hisham
Smith, Ian
Laidlaw, Ian
Khattak, Ilyas
Newby, Jacqueline
Rees-Lee, Jacqueline
Kokan, Jalal
Barrett, Jane
Naik, Jay Dolatrai
Vaidya, Jayant
Forrest, Jennifer
Parmar, Jitendra
Adams, Jocelyn
Fox, John
Roberts, Jonathan
Dawson, Jonathan
Doughty, Julie
Donnelly, Jull
Dunn, Kathleen
Chin, Kian
Horgan, Kieran
Thakur, Kislaya
Barthelmes, Ludger
Wyld, Lynda
Bhattacharyya, Madhumita
Hadaki, Maher
Kishore, Makam
Ornstein, Marcus
Bramley, Maria
Bews-Hair, Maria
Parton, Marina
Sibbering, Mark
Kissin, Mark
Churn, Mark
Hogg, Martin
Quigley, Mary
Hatton, Matthew
Winter, Matthew
Adelekan, Matthew
Shere, Michael
Carr, Michael
Williams, Michael
Absar, Mohammed
Sharif, Muhammad
Kelleher, Muireann
Walji, Nawaz
Williams, Nicholas
Gallegos, Nicholas
Bundred, Nigel
Hatcher, Olivia
Crellin, Perric
Crane, Peter
Donnelly, Peter
Kneeshaw, Peter
Walker, Philip
Sinha, Prakash
Bhaskar, Pudhupalayam
Soulsby, Racheal
Todd, Radha
Vidya, Raghavan
Mehra, Rakesh
Prasad, Ramachandran
Cutress, Ramsay
Sharma, Ravi
Roylance, Rebecca
Goranova, Rebecca
Salman, Reem Ramzi
Bonom, Riccardo
Johnson, Richard
Sutton, Richard
Linforth, Rick
Coleman, Rob
Grieve, Robert
Leonard, Robert
Reichert, Robert
Kennedy, Robert
Agarwal, Roshan
Allerton, Rozenn
Burcombe, Russell
Davis, Ruth
Narayanan, Sankaran
Chandrasekharan, Sankaran
Vesty, Sarah
Seetharam, Seema
Ledwidge, Serena
Iqbal, Shabana
Wahee, Shamaela
Silva, Shobha
Pain, Simon
Holt, Simon
Thomson, Simon
Smith, Simon
Ellenbogen, Simon
Laws, Siobhan
Chan, Stephen
Johnston, Stephen
Holt, Steve
Thrush, Steven
McIntosh, Stuart
Chatterjee, Sumohan
Cleator, Susan
Usman, Tamoor
Johnson, Tayo
Kovacs, Tibor
Irvine, Tracey
Barthkur, Urmila
Pope, Vanessa
Brown, Victoria Alexandra
Muralikrishna, Vummiti
Samra, Walid
Maxwell, William
Winters, Zoe
Bergamino, Milana A.
López-Knowles, Elena
Morani, Gabriele
Tovey, Holly
Kilburn, Lucy
Schuster, Eugene F.
Alataki, Anastasia
Hills, Margaret
Xiao, Hui
Holcombe, Chris
Robertson, John F.
Smith, Ian E.
Bliss, Judith M.
Dowsett, Mitch
Cheang, Maggie C.U.
Źródło:: In eBioMedicine September 2022 83
: Czasopismo naukowe

Full Text Finder

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Informacja

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer